Risk factors for the development of albuminuria and renal impairment in type 2 diabetesthe Swedish National Diabetes Register (NDR)

Nephrology Dialysis Transplantation

Volumn 26, Issue 4, 2011, Pages 1236-1243

  Afghahi, Henri ^a   Cederholm, Jan ^b   Eliasson, Björn ^c   Zethelius, Bjrn ^b   Gudbjrnsdottir, Soffia ^c   Hadimeri, Henrik ^a   Svensson, Maria K ^c  

^a Department of Medicine ^*  (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

albuminuria; obesity; renal impairment; risk factors; type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PULSE PRESSURE; REGISTER; RISK FACTOR; SENESCENCE; SMOKING; SWEDEN; SYSTOLIC BLOOD PRESSURE;

AGED; ALBUMINURIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RISK FACTORS; SWEDEN;

EID: 79953903951     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq535     Document Type: Article

References (42)

1. Brancati FL, Whelton PK, Randall BL et al. Risk of end-stage renal diseaseindiabetes mellitus:aprospective cohort studyofmen screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074 (Pubitemid 28016228)
2. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes melli-tus. N Engl J Med 1999; 341: 1127-1133 (Pubitemid 29466226)
3. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232 (Pubitemid 35463925)
4. Retnakaran R, Cull CA, Thorne KI et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832-1839 (Pubitemid 44324140)
5. Thomas MC, Macisaac RJ, Jerums G et al. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (National Evaluation of the Frequency of Renal Impairment Co-Existing with NIDDM [NEFRON] 11). Diab Care 2009; 32: 1497-1502
6. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
7. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41
8. Ravid M, Brosh D, Ravid-Safran D et al. Main risk factors for ne-phropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998-1004 (Pubitemid 28213577)
9. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albumin-uria, retinopathy and strokes. Kidney Int 2002; 61: 1086-1097 (Pubitemid 34175478)
10. UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713
11. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
12. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301 (Pubitemid 30429874)
13. Lennon R, Pons D, Sabin MA et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic ne-phropathy. Nephrol Dial Transplant 2009; 24: 3288-3296
14. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861
15. Kobayashi H, Tokudome G, Hara Y et al. Insulin resistance is a risk factor for the progression of chronic kidney disease. Clin Nephrol 2009; 71: 643-651
16. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006; 26: 232-244 (Pubitemid 44114394)
17. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol 2009; 20: 293-299
18. Cederholm J, Eliasson B, Nilsson PM et al. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res Clin Pract 2005; 67: 258-266 (Pubitemid 40254316)
19. Forsblom CM, Groop PH, Ekstrand A et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diab Care 1998; 21: 1932-1938 (Pubitemid 28478296)
20. Gall MA, Hougaard P, Borch-Johnsen K et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-788 (Pubitemid 27117048)
21. Clase CM, Garg AX, Kiberd BA. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol 2002; 13: 1338-1349 (Pubitemid 34441415)
22. Stevens PE, O'Donoghue DJ, de Lusignan S et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int 2007; 72: 92-99 (Pubitemid 47014451)
23. Viktorsdottir O, Palsson R, Andresdottir MB et al. Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant 2005; 20: 1799-1807 (Pubitemid 41222591)
24. Evans M, Fryzek JP, Elinder CG et al. The natural history of chronic renal failure: results from an unselected, population-based, inception cohort in Sweden. Am J Kidney Dis 2005; 46: 863-870 (Pubitemid 41505460)
25. WHO. Report of a WHO Consultation. Obesity: preventing and managing the global epidemic. World Health Organ Tech Rep Ser 2000; 894: 1-253
26. Bloomgarden ZT. Blood pressure and diabetic nephropathy. Diab Care 2010; 33: e30-e35
27. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-28 (Pubitemid 46780716)
28. Ejerblad E, Fored CM, Lindblad P et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-1702 (Pubitemid 43794672)
29. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens 2006; 15: 481-486
30. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glome-rulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498-1509
31. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-1777 (Pubitemid 26186610)
32. Bosma RJ, Krikken JA, Homan van der Heide JJ et al. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184-202 (Pubitemid 44298232)
33. Chagnac A, Weinstein T, Herman M et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003; 14: 1480-1486 (Pubitemid 36687049)
34. Navarro-Diaz M, Serra A, Romero R et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 2006; 17: S213-S217 (Pubitemid 44865251)
35. Persson F, Rossing P, Hovind P et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Ir-besartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest 2008; 68: 731-738
36. Valmadrid CT, Klein R, Moss SE et al. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999; 282: 239-246 (Pubitemid 29343166)
37. Kawar B, Bello AK, El Nahas AM. High prevalence of microalbu-minuria in the overweight and obese population: data from a UK population screening programme. Nephron Clin Pract 2009; 112: c205-c212
38. Molnar M, Wittmann I, Nagy J. Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus. Med Sci Monit 2000; 6: 929-936
39. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract 2009; 113: c16-c23
40. MacIsaac RJ, Tsalamandris C, Panagiotopoulos S et al. Nonalbumi-nuric renal insufficiency in type 2 diabetes. Diab Care 2004; 27: 195-200 (Pubitemid 38196732)
41. Nosadini R, Carboni A, Manconi A et al. The decline of glomerular function is not always associated with the development of micro-and macroalbuminuria in hypertensive patients with type 2 diabetes. Diabetologia 2008
42. Ito H, Takeuchi Y, Ishida H et al. High frequencies of diabetic micro-and macroangiopathies in patients with type 2 diabetes mellitus with decreased estimated glomerular filtration rate and normoalbuminuria. Nephrol Dial Transplant 2010; 25: 1161-1167